InnoSkel is a pioneering platform biotechnology company developing therapies for rare skeletal diseases
Our mission
Our goal is to improve skeletal growth and reduce the detrimental complications experienced by individuals with skeletal dysplasia.
Our Approach
We are developing treatment options for a group of rare skeletal disorders known as type 2 collagenopathies, the most severe of which with symptoms present from birth is SEDc, Spondyloepiphyseal Dysplasia congenita.
Our Disease Area
Our lead asset is a gene therapy for SEDc, a disorder characterized by very short stature, severe skeletal and joint malformations, and abnormalities affecting the eyes and ears.
We believe our work has the potential to transform the lives of children affected by SEDc, improving care and preventing harmful complications later in life.
Our News
InnoSkel Launches with €20 Million Series A Financing
InnoSkel today announced that it has raised 20 million in a Series A financing round. The fundraise was co-led by Jeito Capital and Vida Ventures, with additional support from Région Sud Investissement and The Turenne Group.
“Innoskel is committed to developing transformative therapies for patients with skeletal dysplasia who currently have no viable treatment options and experience poor quality of life as a result”
Our Investors
InnoSkel is supported by a number of leading healthcare investors focused on transforming biomedical interventions into therapies:
